Known targets — ChEMBL curated mechanism
ACHECHRM1CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNG
The experimentally established mechanism targets of Iodide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 6/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | DNM1 | Q05193 | 5/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | SLC22A1 | O15245 | 2/20 | 0.32 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Iodide SCHEMBL28614857 | 1.00 | TSHR (0.43) | TSHRLMNATHRBDNM1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL7138382 | 0.96 | TSHR (0.40) | TSHRLMNATHRBDNM1ALDH1A1 | |
| Iodide SCHEMBL10682603 | 0.96 | TSHR (0.40) | TSHRLMNATHRBDNM1ALDH1A1 | |
| SCHEMBL7874985 | 0.96 | TSHR (0.46) | TSHRLMNATHRBDNM1ALDH1A1 | |
| SCHEMBL821221 | 0.96 | TSHR (0.46) | TSHRLMNATHRBDNM1ALDH1A1 | |
| SCHEMBL6033 | 0.96 | TSHR (0.46) | TSHRLMNATHRBDNM1ALDH1A1 | |
| SCHEMBL3110104 | 0.92 | TSHR (0.43) | TSHRLMNATHRBDNM1ALDH1A1 | |
| SCHEMBL7631534 | 0.92 | TSHR (0.43) | TSHRLMNATHRBDNM1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL108265 | 0.92 | TSHR (0.43) | TSHRLMNATHRBDNM1ALDH1A1 | |
| SCHEMBL15656735 | 0.92 | TSHR (0.43) | TSHRLMNATHRBDNM1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10544299-B2 | Vinyl-containing compounds with high heat distortion | REICHHOLD LLC 2 (US) | 2020-01-28 | — | — | US | claimed |
| WO-2014099376-A1 | VINYL CONTAINING COMPOUNDS WITH HIGH HEAT DISTORTION | REICHHOLD, INC. (US) | 2014-06-26 | — | — | WO | claimed |
| US-20140171568-A1 | VINYL-CONTAINING COMPOUNDS WITH HIGH HEAT DISTORTION | Polynt Composites USA Inc. | 2014-06-19 | — | — | US | claimed |
| CN-115155656-A | Catalyst for synthesizing cyclic carbonate and synthetic method of cyclic carbonate | 深圳新宙邦科技股份有限公司 | 2022-10-11 | — | — | CN | disclosed |
| US-10962703-B1 | Nanoparticle dispersion for increasing optical index of refraction | FACEBOOK TECHNOLOGIES, LLC (US) | 2021-03-30 | — | — | US | disclosed |
| US-10544299-B2 | Vinyl-containing compounds with high heat distortion | REICHHOLD LLC 2 (US) | 2020-01-28 | — | — | US | disclosed |
| EP-3002312-B1 | CURABLE COMPOSITIONS | REICHHOLD LLC 2 (US) | 2018-08-29 | — | — | EP | disclosed |
| US-20180223039-A1 | CURABLE COMPOSITIONS | REICHHOLD LLC 2 | 2018-08-09 | — | — | US | disclosed |
| US-10000602-B2 | Curable compositions | REICHHOLD LLC 2 (US) | 2018-06-19 | — | — | US | disclosed |
| US-20160096918-A1 | CURABLE COMPOSITIONS | Polynt Composites USA Inc. | 2016-04-07 | — | — | US | disclosed |
| EP-3002312-A1 | CURABLE COMPOSITIONS | Reichhold LLC 2 (US) | 2016-04-06 | — | — | EP | disclosed |
| US-20080317877-A1 | Biofilm Remover | WHITELEY CORPORATION PTY. LTD. (AU) | 2008-12-25 | — | — | US | disclosed |
| US-20080108828-A1 | Optically Active 4,4-Di-Substituted Oxazolidine Derivative and Method for Producing Same | SANKYO COMPANY, LIMITED (JP) | 2008-05-08 | — | — | US | disclosed |
| EP-1806344-A1 | OPTICALLY ACTIVE 4,4-DISUBSTITUTED OXAZOLIDINE DERIVATIVE AND METHOD FOR PRODUCING SAME | Sankyo Company, Limited (JP) | 2007-07-11 | — | — | EP | disclosed |
| WO-2001027183-A1 | PREPARATION OF ACRYLIC COMPOUNDS CONTAINING RESINS WITH VINYL FUNCTIONALITY | REICHHOLD, INC. (US) | 2001-04-19 | — | — | WO | disclosed |
| US-5998568-A | REACTING POLYALCOHOL OR POLYTHIOL WITH CYCLIC CARBONATE IN PRESENCE OF A CATALYST | REICHHOLD, INC. (US) | 1999-12-07 | — | — | US | disclosed |
| EP-0002590-B1 | NOVEL PROSTAGLANDIN COMPOUNDS, PROCESSES FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | AMERICAN CYANAMID COMPANY (US) | 1981-09-30 | — | — | EP | disclosed |
| US-4230879-A | 15-Deoxy-16-hydroxy-16-formyo or dimethoxy-methyl-prostane derivatives of the E and F series | AMERICAN CYANAMID COMPANY (US) | 1980-10-28 | — | — | US | disclosed |
| US-4227011-A | 15-Deoxy-16-hydroxy-16-chloromethyl or bromomethyl prostaglandins of the E and F series | AMERICAN CYANAMID COMPANY (US) | 1980-10-07 | — | — | US | disclosed |
| EP-0013107-A1 | 16-Hydroxy-16-vinyl (or cyclopropyl)-prostan-1-ols and pharmaceutical compositions containing the same | AMERICAN CYANAMID COMPANY (US) | 1980-07-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080108828-A1 | Optically Active 4,4-Di-Substituted Oxazolidine Derivative and Method for Producing Same | CBR3, C9, COX6C | TSHR 1739/4885LMNA 2710/4885THRB 2917/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.